Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 1401

1.

Incretin hormone secretion in women with polycystic ovary syndrome: roles of obesity, insulin sensitivity, and treatment with metformin.

Svendsen PF, Nilas L, Madsbad S, Holst JJ.

Metabolism. 2009 May;58(5):586-93. doi: 10.1016/j.metabol.2008.11.009.

PMID:
19375579
2.

Normal secretion of the incretin hormones glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 during gestational diabetes mellitus.

Cypryk K, Vilsbøll T, Nadel I, Smyczyńska J, Holst JJ, Lewiński A.

Gynecol Endocrinol. 2007 Jan;23(1):58-62.

PMID:
17484514
3.

The effects of miglitol on glucagon-like peptide-1 secretion and appetite sensations in obese type 2 diabetics.

Lee A, Patrick P, Wishart J, Horowitz M, Morley JE.

Diabetes Obes Metab. 2002 Sep;4(5):329-35.

PMID:
12190996
4.

The entero-insular axis in polycystic ovarian syndrome.

Gama R, Norris F, Wright J, Morgan L, Hampton S, Watkins S, Marks V.

Ann Clin Biochem. 1996 May;33 ( Pt 3):190-5.

PMID:
8791980
5.

Secretion of incretin hormones (GIP and GLP-1) and incretin effect after oral glucose in first-degree relatives of patients with type 2 diabetes.

Nauck MA, El-Ouaghlidi A, Gabrys B, Hücking K, Holst JJ, Deacon CF, Gallwitz B, Schmidt WE, Meier JJ.

Regul Pept. 2004 Nov 15;122(3):209-17.

PMID:
15491793
6.

Defective amplification of the late phase insulin response to glucose by GIP in obese Type II diabetic patients.

Vilsbøll T, Krarup T, Madsbad S, Holst JJ.

Diabetologia. 2002 Aug;45(8):1111-9. Epub 2002 Jul 4.

PMID:
12189441
7.

The incretin effect and secretion in obese and lean women with polycystic ovary syndrome: a pilot study.

Pontikis C, Yavropoulou MP, Toulis KA, Kotsa K, Kazakos K, Papazisi A, Gotzamani-Psarakou A, Yovos JG.

J Womens Health (Larchmt). 2011 Jun;20(6):971-6. doi: 10.1089/jwh.2010.2272.

PMID:
21671782
8.

Obesity, body composition and metabolic disturbances in polycystic ovary syndrome.

Svendsen PF, Nilas L, Nørgaard K, Jensen JE, Madsbad S.

Hum Reprod. 2008 Sep;23(9):2113-21. doi: 10.1093/humrep/den211. Epub 2008 Jun 12.

PMID:
18556679
9.

Incretin levels in polycystic ovary syndrome.

Vrbikova J, Hill M, Bendlova B, Grimmichova T, Dvorakova K, Vondra K, Pacini G.

Eur J Endocrinol. 2008 Aug;159(2):121-7. doi: 10.1530/EJE-08-0097. Epub 2008 May 29.

PMID:
18511472
10.

Alteration of ghrelin-neuropeptide Y network in obese patients with polycystic ovary syndrome: role of hyperinsulinism.

Romualdi D, De Marinis L, Campagna G, Proto C, Lanzone A, Guido M.

Clin Endocrinol (Oxf). 2008 Oct;69(4):562-7. doi: 10.1111/j.1365-2265.2008.03204.x. Epub 2008 Jan 31.

PMID:
18248643
11.

Adiponectin levels in women with polycystic ovary syndrome and severe insulin resistance.

Sepilian V, Nagamani M.

J Soc Gynecol Investig. 2005 Feb;12(2):129-34.

PMID:
15695109
12.

Predictors of incretin concentrations in subjects with normal, impaired, and diabetic glucose tolerance.

Vollmer K, Holst JJ, Baller B, Ellrichmann M, Nauck MA, Schmidt WE, Meier JJ.

Diabetes. 2008 Mar;57(3):678-87. Epub 2007 Dec 5.

13.
14.

Insulin sensitizing drugs increase the endogenous dopaminergic tone in obese insulin-resistant women with polycystic ovary syndrome.

Ortega-González C, Cardoza L, Coutiño B, Hidalgo R, Arteaga-Troncoso G, Parra A.

J Endocrinol. 2005 Jan;184(1):233-9.

PMID:
15642799
15.

Effect of metformin on the growth hormone response to growth hormone-releasing hormone in obese women with polycystic ovary syndrome.

Guido M, Romualdi D, Giuliani M, Suriano R, Tienforti D, Costantini B, Lanzone A.

Fertil Steril. 2005 Nov;84(5):1470-6.

PMID:
16275246
16.

Effects of metformin and rosiglitazone, alone and in combination, in nonobese women with polycystic ovary syndrome and normal indices of insulin sensitivity.

Baillargeon JP, Jakubowicz DJ, Iuorno MJ, Jakubowicz S, Nestler JE.

Fertil Steril. 2004 Oct;82(4):893-902.

PMID:
15482765
17.

Effects of metformin on glucagon-like peptide-1 levels in obese patients with and without Type 2 diabetes.

Mannucci E, Tesi F, Bardini G, Ognibene A, Petracca MG, Ciani S, Pezzatini A, Brogi M, Dicembrini I, Cremasco F, Messeri G, Rotella CM.

Diabetes Nutr Metab. 2004 Dec;17(6):336-42.

PMID:
15887627
18.

Metformin decreases the adipokine vaspin in overweight women with polycystic ovary syndrome concomitant with improvement in insulin sensitivity and a decrease in insulin resistance.

Tan BK, Heutling D, Chen J, Farhatullah S, Adya R, Keay SD, Kennedy CR, Lehnert H, Randeva HS.

Diabetes. 2008 Jun;57(6):1501-7. doi: 10.2337/db08-0127. Epub 2008 Mar 28.

19.

Metformin versus flutamide in the treatment of metabolic consequences of non-obese young women with polycystic ovary syndrome: a randomized prospective study.

Sahin I, Serter R, Karakurt F, Demirbas B, Culha C, Taskapan C, Kosar F, Aral Y.

Gynecol Endocrinol. 2004 Sep;19(3):115-24.

PMID:
15697072
20.

[Metformin, an efficacious drug in the treatment of polycystic ovary syndrome].

Hahn S, Quadbeck B, Elsenbruch S, Gärtner R, Finke R, Mann K, Janssen OE.

Dtsch Med Wochenschr. 2004 May 7;129(19):1059-64. German.

PMID:
15136950

Supplemental Content

Support Center